Neurosciences Company Reports Potential for Improved Safety Profile for Alzheimer’s Treatment

Source: Streetwise Reports   08/29/2018 The substance shows potential for an improved safety profile in direct comparison to other Amyloid Beta-Directed Antibodies in clinical development. ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB), a biotechnology company focused on the [...]
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.